Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Mar 28, 2018
Open Peer Review Period: Mar 28, 2018 - May 12, 2018
Date Accepted: May 12, 2018
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

A Digital Decision Support Tool to Enhance Decisional Capacity for Clinical Trial Consent: Design and Development

Furberg RD, Ortiz AM, Moultrie RR, Raspa M, Wheeler AC, McCormack LA, Bailey DB Jr

A Digital Decision Support Tool to Enhance Decisional Capacity for Clinical Trial Consent: Design and Development

JMIR Res Protoc 2018;7(6):e10525

DOI: 10.2196/10525

PMID: 29875084

PMCID: 6010840

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

A Digital Decision Support Tool to Enhance Decisional Capacity for Clinical Trial Consent: Design and Development

  • Robert D Furberg; 
  • Alexa M Ortiz; 
  • Rebecca R Moultrie; 
  • Melissa Raspa; 
  • Anne C Wheeler; 
  • Lauren A McCormack; 
  • Donald B Bailey Jr

Background:

Challenges in the clinical and research consent process indicate the need to develop tailored, supportive interventions for all individuals, especially those with limited decisional capacity. We developed a tool to enhance shared decision making and the decisional capacity for individuals with fragile X syndrome engaged in the informed consent process for a clinical trial.

Objective:

We describe the design and development process of a tablet-based decision support tool.

Methods:

Our development process for the decision support tool employed a user-centered, feature-driven design approach. We began with an environmental scan to catalog relevant mobile apps, and we conducted interviews with people with a diagnosis of fragile X syndrome and clinicians at fragile X syndrome clinics. To develop content for the decision support tool, we extracted key concepts and elements from a real clinical trial consent form and rewrote it using plain-language principles.

Results:

We used iterative testing to continuously evaluate and revise the decision support tool content. The tool was finalized in 2016 and contained a series of vignettes, quiz questions, and a sorting activity. A randomized controlled trial was then conducted to compare the efficacy of the decision support tool with a standard verbal presentation of material that mimicked typical informed consent practice.

Conclusions:

The informed consent process is primed to leverage digital health resources that promote increased understanding and engagement of research participants in the consent and research process. The process and experiences we describe may provide a model for other digital health design and development initiatives seeking to create more interactive and accessible decision support resources.

ClinicalTrial:

ClinicalTrials.gov NCT02465931; https://www.clinicaltrials.gov/ct2/show/NCT02465931 (Archived by WebCite at http://www.webcitation.org/6zx2KY9YW)


 Citation

Please cite as:

Furberg RD, Ortiz AM, Moultrie RR, Raspa M, Wheeler AC, McCormack LA, Bailey DB Jr

A Digital Decision Support Tool to Enhance Decisional Capacity for Clinical Trial Consent: Design and Development

JMIR Res Protoc 2018;7(6):e10525

DOI: 10.2196/10525

PMID: 29875084

PMCID: 6010840

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.